Quince Therapeutics Eyes Capital-Efficient Path to NEAT Data as A-T Trial Nears Enrollment Milestone Strategic Shift Aims to Maximize Resources and Deliver Phase 3 Data by Early 2026 Quince Therapeutics (NASDAQ: QNCX) reported first quarter 2025 results whil

Quince Therapeutics #QNCX is considering an early enrollment close for its Phase 3 NEAT trial of EryDex in A-T to align with its current cash runway.
#QuinceTherapeutics
Read more: prismmarketview.com/quince-thera...